
    
      The purpose of the study is to compare efficacy of DCVAC/LuCa + chemotherapy +/- immune
      enhancers vs. Standard of Care chemotherapy alone in patients with stage IV NSCLC, as
      measured by progression free survival (PFS).
    
  